Commentary · 21 Feb 2026
Conference abstractPublished 28 Sep 2015
Chronic Myelgenous Leukemia: Epidemiological Characteristics and Chemotherapy Approaches in the Republic of Moldova
State University of Medicine and Pharmacy âÂ?Â?N. TestemitanuâÂ?, Institute of Oncology, Republic of Moldova
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
This descriptive and clinico-analytic study comprized 125 patients with chronic myelogenous leukemia (CML), who had been followed up at the Institute of Oncology between 2002 âÂ?Â? 2013. The diagnosis was established in chronic phase in 113 (90,4 Ã?± 2,32%) cases, in accelerated and acute phases in 12 (9,6 Ã?± 2,02%). The patient age ranged between 19 âÂ?Â? 81 years, with the most frequently affected group of 40 âÂ?Â? 49 years (27.4 Ã?± 4.89%). The median age was 46.1 Ã?± 2.13 years old. The median male/ female ratio was 1.4:1, with the age-adjusted limits of 1.1 âÂ?Â? 1.8:1. In spite of the slow incidence increase (2010 âÂ?Â? 0,81%ooo, 2014 âÂ?Â? 0.83%ooo), the prevalence of CML grew progressively (2005 âÂ?Â? 2.11%ooo, 2014 âÂ?Â? 4.16%ooo). The northern (27 patients / 32.1 Ã?± 5.10%) and central (25 patients / 29.8 Ã?± 4.99%) regions population proved to be mainly affected by CML. 50 (59.6 Ã?± 4.99%) patients were exposed to insolation during professional activities and daily life (correlation coefficient 0.479). The discriminant analysis of the late diagnosis factors revealed the higher coefficient of canonical correlation for asymptomatic /oligosymptomatic onset of the disease (0.548). 81 (64.8%) patients were approved for GIPAP, and 4 (4.0%) âÂ?Â? for NOAT Program. The enrollment in GIPAP and NOAT Program, with imatinib and nilotinib therapies significantly improved (p<0.01) the performance status in 90.5% of patients (ECOG-WHO score 0 âÂ?Â? 1, PÃ?±ES% = 0.25 Ã?± 0.06), as compared to the non-TKIs chemotherapy. The overall 3-year survival in TKIs -treated patients (66.0%) outstripped (p<0.05) that one obtained under the non-TKIs chemotherapy (44.5%).
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Vasile Musteata”
